Wife turns cold-blooded killer for 'Apadbandhava Ashok'; missing mystery solved

Mangaluru, May 27: Karnataka’s twin coastal districts of Dakshina Kannada and Udupi today reported 11 and 9 fresh covid-19 cases respectively.

In Dakshina Kannada the covid-19 patients include seven women and four men who had recently come from Maharashtra.

One of the patients is a 3-year-old child. Others are girls aged 11 and 17, women aged 36, 37, 45, 59 and men aged 22, 35, 39 and 46.

All of them have been shifted to covid-19 hospital from different institutional quarantine centres. 

In Udupi too all the nine people – six men, a boy, and two women -  had come from Maharashtra a few days ago.

Bengaluru, Mar 26: In a second coronavirus related death in Karnataka, COVID-19 test results of a 75- year-old woman who had died on Wednesday has come out as positive, Medical Education Minister K Sudhakar said.

"I regret to inform that the COVID-19 test result has come out as positive for patient, who had succumbed to death yesterday. The govt stands committed to curb the spread of Corona Virus in the state. Please stay home, stay safe," Sudhakar tweeted on Thursday.

Health and Family Welfare Minister B Sriramulu too said the lab reports regarding the death on Wednesday have come and it has come out as positive, and death was due to COVID-19.

The exact cause of her death would be known only after the final report comes, both Minister had said on Wednesday.

The woman from Gauribidanur in Chikkaballapura district, had returned from Mecca in Saudi Arabia recently.

Sharing details about the woman, Sriramulu in a tweet on Wednesday had said, she died at Bowring hospital here at 1 am, and was suffering from diabetes, chest pain and hip fracture.

The patient was undergoing treatment in isolation ward at a hospital in Gauribidanur, later for more treatment she was shifted to Rajiv Gandhi Institute of Chest Diseases in Bengaluru, from where she was shifted to Bowring hospital on Tuesday," he had said.

This is the second coronavirus fatality in the state.

Earlier this month, a 76-year old Kalaburagi man died "due to co-morbidity and was also tested positive for COVID- 19", becoming the country's first coronavirus death.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.